MARCHESELLI, Luigi
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.211
EU - Europa 7.148
AS - Asia 4.500
OC - Oceania 498
SA - Sud America 395
AF - Africa 189
Continente sconosciuto - Info sul continente non disponibili 11
Totale 26.952
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.781
GB - Regno Unito 2.770
IT - Italia 937
SG - Singapore 797
CN - Cina 744
DE - Germania 707
SE - Svezia 582
PH - Filippine 486
HK - Hong Kong 475
AU - Australia 462
TR - Turchia 419
CA - Canada 352
RU - Federazione Russa 318
BR - Brasile 308
FR - Francia 293
UA - Ucraina 262
IR - Iran 261
FI - Finlandia 253
IN - India 154
ID - Indonesia 134
IE - Irlanda 131
PK - Pakistan 126
BG - Bulgaria 113
NL - Olanda 109
VN - Vietnam 108
MY - Malesia 103
JP - Giappone 97
KR - Corea 91
GR - Grecia 88
ES - Italia 81
TW - Taiwan 80
IL - Israele 74
BE - Belgio 65
PL - Polonia 63
SA - Arabia Saudita 61
AT - Austria 53
TH - Thailandia 51
ZA - Sudafrica 46
GE - Georgia 39
RO - Romania 39
NO - Norvegia 37
NP - Nepal 37
NZ - Nuova Zelanda 36
LK - Sri Lanka 35
MA - Marocco 34
MX - Messico 33
LV - Lettonia 32
CH - Svizzera 30
KE - Kenya 26
EE - Estonia 24
LT - Lituania 24
PT - Portogallo 23
JO - Giordania 22
CZ - Repubblica Ceca 21
AR - Argentina 20
HR - Croazia 19
NG - Nigeria 18
EG - Egitto 17
HU - Ungheria 17
SK - Slovacchia (Repubblica Slovacca) 17
SI - Slovenia 15
BZ - Belize 14
CL - Cile 14
EC - Ecuador 14
PE - Perù 12
CO - Colombia 11
BD - Bangladesh 10
AE - Emirati Arabi Uniti 9
DK - Danimarca 9
CY - Cipro 8
IQ - Iraq 8
OM - Oman 8
TN - Tunisia 8
PR - Porto Rico 7
UZ - Uzbekistan 7
A2 - ???statistics.table.value.countryCode.A2??? 6
ET - Etiopia 6
MO - Macao, regione amministrativa speciale della Cina 6
MU - Mauritius 6
MV - Maldive 6
BH - Bahrain 5
BO - Bolivia 5
GY - Guiana 5
KZ - Kazakistan 5
LB - Libano 5
PA - Panama 5
PS - Palestinian Territory 5
DZ - Algeria 4
EU - Europa 4
KW - Kuwait 4
NA - Namibia 4
QA - Qatar 4
SD - Sudan 4
TT - Trinidad e Tobago 4
AZ - Azerbaigian 3
CR - Costa Rica 3
GH - Ghana 3
GP - Guadalupe 3
KG - Kirghizistan 3
MT - Malta 3
Totale 26.900
Salva come PNG Salva come JPEG
Città #
Fairfield 1.815
Southend 1.619
Santa Clara 1.268
Woodbridge 1.142
Ashburn 996
Chandler 839
Houston 809
Seattle 678
Wilmington 643
Cambridge 587
Jacksonville 503
Singapore 446
Dearborn 428
Ann Arbor 404
Hong Kong 401
Nyköping 401
London 318
Modena 226
Beijing 196
Redwood City 183
Frankfurt am Main 182
San Diego 178
Helsinki 161
New York 153
Izmir 147
Munich 120
Princeton 116
Sofia 111
Melbourne 98
Eugene 96
Council Bluffs 95
Moscow 93
Jakarta 77
Dublin 73
Shanghai 73
Milan 60
Bremen 59
Brisbane 59
Ottawa 59
Sydney 58
Hefei 56
Istanbul 54
Bologna 48
Falls Church 46
Taipei 46
Liverpool 43
Paris 41
Athens 39
Brussels 37
Des Moines 37
Fremont 37
Los Angeles 37
The Dalles 37
Hanoi 36
Tehran 35
Dong Ket 34
Quezon City 34
Perth 30
Chicago 29
Tokyo 29
Norwalk 28
Riga 28
Cebu City 27
Islamabad 26
Manila 26
Phoenix 26
Colombo 25
Riyadh 25
São Paulo 25
Vienna 25
Greenwich 24
Ho Chi Minh City 24
Karachi 24
Kuala Lumpur 24
Nanjing 24
Rome 24
San Giuliano Milanese 24
Toronto 24
Birmingham 23
Tbilisi 23
Kuching 22
Laval 22
San Jose 22
Antalya 21
Boardman 21
Cagayan de Oro 21
Kathmandu 21
Bangkok 20
Bengaluru 20
Lahore 20
Parma 20
Davao City 19
Seoul 19
Guangzhou 18
Kunming 18
Ankara 17
Tallinn 17
Warsaw 17
Makati City 16
Southwark 16
Totale 17.641
Salva come PNG Salva come JPEG
Nome #
Empathy and burnout: an analytic cross-sectional study among nurses and nursing students 6.235
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lmphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi 550
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma 543
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 540
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 362
The impact of shift work on the psychological and physical health of nurses in a general hospital: a comparison between rotating night shifts and day shifts 332
N,N-DIMETHYLFORMAMIDE-2-METHOXYETHANOL SOLVENT SYSTEM - DENSITIES AND EXCESS MOLAR VOLUMES AT VARIOUS TEMPERATURES 304
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 289
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 278
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 276
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: Evaluation based on data from 1450 patients 273
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines 270
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. 268
Incidence, clinical features and possible etiology of early onset (≤40 years) colorectal neoplasms. 265
Empathic attitudes among nursing students: a preliminary study 262
The outcome of peripheral t-cell lymphoma patients failing first-line therapy: A report from the prospective, international t-cell project 260
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy 257
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. 251
Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine 249
Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines 246
Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network 246
Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma 245
ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. 243
Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. 234
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 228
A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias. 227
Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project 226
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 225
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 224
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 224
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 222
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 220
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. 219
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies 219
Lymph node evaluation in stage IIA colorectal cancer and its impact on patient prognosis: A population-based study 217
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy 216
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 214
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis 211
Cancer incidence, mortality, and survival in Eastern Libya: Updated report from the Benghazi Cancer Registry 210
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 210
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma 206
Role of Glutathione-S-Transferase (GST) polymorphisms in patients with advanced Hodgkin Lymphoma: results from the HD2000 GISL Trial 204
Identification of protein clusters predictive of response to chemotherapy in breast cancer patients 202
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines 202
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma 201
Multicentre validation of an immune-inflammation-based nomogram to predict survival in western resectable gastroesophageal adenocarcinoma: The NOMOGAST 200
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi 199
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study 198
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study 197
Reproductive risk factors in women with family history of breast cancer attending an Italian Family Cancer Clinic 197
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi 197
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 194
Prognostic relevance of microsatellite instability in pT3N0M0 colon cancer: a population-based study 194
Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pilori interventions: results from a population-based study on extranodal marginal zone lymphomas 193
Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced hodgkin lymphoma: A study by fondazione Italiana Linfomi 192
Brca detection rate in an italian cohort of luminal early-onset and triple-negative breast cancer patients without family history: When biology overcomes genealogy 192
Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. 190
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfom 190
A NON-LINEAR CORRELATION MODEL FOR THE RELATIVE PERMITTIVITY OF TERNARY AMPHIPROTIC (SOLVENT) MIXTURES 188
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial 188
Estimating survival in newly diagnosed cancer patients: use of computer simulations to evaluate performances of different approaches in a wide range of scenarios. 187
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 184
Lifestyle intervention on body weight and physical activity in patients with breast cancer can reduce the risk of death in obese women: The EMILI study 184
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study 182
The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL) 181
2-methoxyethanol - water solvent system : static relative permittivity from -10 to 80°C 180
ANALYSIS OF HEAVY-METALS IN ACETO-BALSAMICO-TRADIZIONALE-DI-MODENA BY FLAME ATOMIC-ABSORPTION SPECTROSCOPY 179
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era 179
Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: Results from a study of the Fondazione Italiana Linfomi 178
Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi 177
Standard “off-the-shelf” multibranched thoracoabdominal endograft in urgent and elective patients with single and staged procedures in a multicenter experience 172
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation 172
Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. 171
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 170
A model for predicting the risk of developing mild anemia (MA) in patients with lymphoid malignancy. A study of the Gruppo Italiano Studio Linfomi (GISL) 170
The relative permittivity of the ternary 1,2-ethanediol + 2-methoxyethanol + water solvent system 166
CLIPI: a new prognostic index for indolent cutaneos B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) 166
Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies 165
Dielectric properties of ethane-1,2-diol + 2-methoxyethanol + water liquid ternary mixtures 163
Twenty-years experience with de novo metastatic breast cancer 163
Watchful waiting in low-tumorburden follicular lymphoma in the Rituximab era. Results of a F2 observational 162
Phase II Fludarabine and Cyclophosphamide for the treatment of indolent cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi. 160
Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study) 154
Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial. 153
Durability and efficacy of tibial arterial stent placement for critical limb ischemia 152
VALIDATION OF ABSOLUTE LYMPHOCYTE COUNT / REVISED IPI (ALC/R-IPI) SCORE MODEL, AS A PROGNOSTIC INDEX FOR DIFFUSE LARGE-B-CELL LYMPHOMA IN RITUXIMAB ERA 148
Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination 144
Treatment of patients with recurrent follicular lymphoma with rituximab in combination with fludarabine and cyclophosphamide 141
I tumori nelle provincie di Parma, Reggio Emilia, Modena 140
Introduction of Combined Chemotherapies Plus Rituximab (R) Has Improved Outcome of Previously Untreated and Relapsed Follicular Lymphoma (FL) Patients (pts).. 139
BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience 134
The Relative Permittivity of N,N-Dimethylformamide/1,2-Dimethoxyethane Binary Mixtures from -10 to 40 C 133
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 132
The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy 132
Rituximab in combination with chemotherapy has improved survival of patients with follicular lymphoma 124
Influence of Thoracic Endovascular Repair on Aortic Morphology in Patients Treated for Blunt Traumatic Aortic Injuries: Long Term Outcomes in a Multicentre Study 118
Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma 113
Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL) 112
Contemporary economic and clinical evaluations of endovascular repair for intact descending thoracic aortic aneurysms 110
Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas 106
Totale 26.910
Salva come PNG Salva come JPEG
Categoria #
all - tutte 93.239
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 93.239
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020439 0 0 0 0 0 0 0 0 0 0 251 188
2020/20214.312 350 180 369 436 515 373 284 439 293 452 371 250
2021/20223.136 194 240 388 194 143 218 170 207 338 260 489 295
2022/20233.279 285 357 233 328 359 401 144 304 390 151 180 147
2023/20243.220 111 149 218 250 622 263 469 377 110 180 218 253
2024/20254.866 195 113 193 476 1.102 779 476 436 680 269 147 0
Totale 27.364